NPCE - Neuropace Inc logo

Neuropace Inc

NPCE

NeuroPace develops medical devices for epilepsy treatment, focusing on its RNS system, which delivers real-time neuromodulation to manage drug-resistant focal epilepsy. Its products include neurostimulators, leads, and patient monitoring tools used in hospitals.

⚕️ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago →$828today

Score Overview

1 Year
Score
Net Growth10.95%
Net TrendGrew
Net Income Consistency—
Rev Growth-1.15%
Rev TrendShrank
Revenue Consistency—
5 Years
Score6.9
Net Growth47.02%
Net Trend80%
Net Income Consistency—
Rev Growth118.75%
Rev Trend80%
Revenue Consistency—
All Time
Score
Net Growth47.02%
Net Trend80%
Net Income Consistency
Rev Growth118.75%
Rev Trend80%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Neuropace Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. NPCE does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 12.91—
1 Year2025-10-23
$ 10.5522.37%
5 Years2021-10-22
$ 15.59-17.19%
All Time2021-04-22
$ 24.96-48.28%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 98M-$ 19M$ 51M
2025$ 99M-$ 21M$ 61M
2024$ 79M-$ 27M$ 52M
2023$ 65M-$ 32M$ 66M
2022$ 45M-$ 47M$ 77M
IPO2021$ 45M-$ 36M$ 115M
NPCE - Neuropace Inc logo

Neuropace Inc fundamental performance

Between 2021 and 2025, revenue grew from $ 45M to $ 99M and net income went from -$ 36M to -$ 21M. Revenue increased in 80% of the years measured; net income in 80%.

Neuropace Inc currently holds a 5-year HDB Score of 6.9 out of 10. How the HDB Score is calculated.

Membership

Explore NPCE with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies